BNTX Financials: Biontech SE AI Analysis



Financials

BNTX Financial

Biontech SE

$92.18

0.9%

$0.83

At close: Aug 05, 16:00:00 GMT-4

$92.18

Post-market: Aug 05, 17:09:01 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$91.35

Open

$91.42

Day's Range

$90.4 - $92.96

52 week range

$79.52 - $124

Volume

1.5M

Avg.Volume

1.1M

Dividend yield

0.00%

EPS (TTM)

-5.70

Market Cap

$23.3B

What is BNTX?

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Features

Markets

News

Breakdown	TTM	03/31/2026	12/31/2025	09/30/2025	06/30/2025	03/31/2025
Revenue	2,805	118	907	1,518	260	182
Revenue Growth (YoY)	2%	-35%	-24%	22%	103%	-3%
Cost of Revenue	503	70	246	136	49	46
Gross Profit	2,302	47	660	1,382	211	136
Selling, General & Admin	654	150	217	148	137	120
Research & Development	2,136	557	505	564	509	525
Operating Expenses	2,931	722	800	727	681	648
Other Non Operating Income (Expenses)	3	--	7	0	-3	-6
Pretax Income	-1,173	-568	-227	24	-402	-445
Income Tax Expense	78	-36	77	53	-16	-29
Net Income	-1,252	-531	-305	-28	-386	-415
Net Income Growth	63%	28%	-218%	-113.99%	-52%	32%
Shares Outstanding (Diluted)	253.28	253.28	244.1	239.16	241.62	240.34
Shares Change (YoY)	5%	5%	3%	-2%	1%	0%
EPS (Diluted)	-4.94	-2.1	-1.24	-0.12	-1.6	-1.73
EPS Growth	55%	21%	-214%	-114.99%	-52%	32%
Free Cash Flow	605	-499	247	742	116	-1,398
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	82.06%	39.83%	72.76%	91.04%	81.15%	74.72%
Operating Margin	-22.42%	-571.18%	-15.32%	43.14%	-180.76%	-280.76%
Profit Margin	-44.63%	-450%	-33.62%	-1.84%	-148.46%	-228.02%
Free Cash Flow Margin	21.56%	-422.88%	27.23%	48.88%	44.61%	-768.13%
EBITDA	-168	-553	25	779	-419	-469
EBITDA Margin	-5.98%	-468.64%	2.75%	51.31%	-161.15%	-257.69%
D&A For EBITDA	461	121	164	124	51	42
EBIT	-629	-674	-139	655	-470	-511
EBIT Margin	-22.42%	-571.18%	-15.32%	43.14%	-180.76%	-280.76%
Effective Tax Rate	-6.64%	6.33%	-33.92%	220.83%	3.98%	6.51%

Breakdown

TTM

03/31/2026

12/31/2025

09/30/2025

06/30/2025

03/31/2025

Revenue

2,805

118

907

1,518

260

182

Revenue Growth (YoY)

-35%

-24%

22%

103%

-3%

Cost of Revenue

503

246

136

Gross Profit

2,302

660

1,382

211

136

Selling, General & Admin

654

150

217

148

137

120

Research & Development

2,136

557

505

564

509

525

Operating Expenses

2,931

722

800

727

681

648

Other Non Operating Income (Expenses)

-3

-6

Pretax Income

-1,173

-568

-227

-402

-445

Income Tax Expense

-36

-16

-29

Net Income

-1,252

-531

-305

-28

-386

-415

Net Income Growth

63%

28%

-218%

-113.99%

-52%

32%

Shares Outstanding (Diluted)

253.28

244.1

239.16

241.62

240.34

Shares Change (YoY)

-2%

EPS (Diluted)

-4.94

-2.1

-1.24

-0.12

-1.6

-1.73

EPS Growth

55%

21%

-214%

-114.99%

-52%

32%

Free Cash Flow

605

-499

247

742

116

-1,398

Free Cash Flow Per Share

Gross Margin

82.06%

39.83%

72.76%

91.04%

81.15%

74.72%

Operating Margin

-22.42%

-571.18%

-15.32%

43.14%

-180.76%

-280.76%

Profit Margin

-44.63%

-450%

-33.62%

-1.84%

-148.46%

-228.02%

Free Cash Flow Margin

21.56%

-422.88%

27.23%

48.88%

44.61%

-768.13%

EBITDA

-168

-553

779

-419

-469

EBITDA Margin

-5.98%

-468.64%

2.75%

51.31%

-161.15%

-257.69%

D&A For EBITDA

461

121

164

124

EBIT

-629

-674

-139

655

-470

-511

EBIT Margin

-22.42%

-571.18%

-15.32%

43.14%

-180.76%

-280.76%

Effective Tax Rate

-6.64%

6.33%

-33.92%

220.83%

3.98%

6.51%

Follow-Up Questions

What are Biontech SE's key financial statements?



According to the latest financial statement (Form-10K), Biontech SE has a total asset of $0, Net loss of $0

What are the key financial ratios for BNTX?



Biontech SE's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is Biontech SE's revenue broken down by segment or geography?



Currently Biontech SE data is not available.

Is Biontech SE profitable?



no, according to the latest financial statements, Biontech SE has a net loss of $0

Does Biontech SE have any liabilities?



no, Biontech SE has liability of 0

How many outstanding shares for Biontech SE?



Biontech SE has a total outstanding shares of 0

Biontech SE (BNTX) Financial

BNTX Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is BNTX?

Biontech SE (BNTX) Financial

BNTX Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is BNTX?

BNTX Income

Follow-Up Questions

What are Biontech SE's key financial statements?

What are the key financial ratios for BNTX?

How is Biontech SE's revenue broken down by segment or geography?

Is Biontech SE profitable?

Does Biontech SE have any liabilities?

How many outstanding shares for Biontech SE?